• Jung Eun Lee, Kang Ryul Min, Soo Hyun Kim, Alec Hyungtack Kim, and Seong Taek Kim.
• Department of Orofacial Pain and Oral Medicine, Yonsei University College of Dentistry, Seoul, Korea.
• Yonsei Med. J. 2020 Oct 1; 61 (10): 875-879.

PurposeTo describe adverse drug reactions (ADRs) to carbamazepine (CBZ) and oxcarbazepine (OXC), including severe cutaneous ADRs, at a tertiary care hospital over a 10-year period.Materials And MethodsThe frequency and clinical features of ADRs caused by CBZ and OXC were analyzed using the pharmacovigilance database and spontaneous ADR reporting data of Yonsei University Severance Hospital & Dental Hospital (Seoul, Korea) from January 1, 2010 to January 31, 2020.ResultsAmong 10419 cases prescribed CBZ and OXC, 204 ADR cases were reported. The incidences of ADRs were 1.8% and 2.2% for CBZ and OXC respectively, with no significant difference (p=0.169). The most common clinical presentations were skin disorders. Female patients had relatively more frequent ADRs than male patients. Although mild skin ADRs were more frequent with OXC, nervous system disorders, general disorders, and hepatobiliary disorders occurred more often with CBZ. There were six reports of severe cutaneous adverse reactions to CBZ, while OXC had none. Both CBZ and OXC caused ADRs at daily doses lower than the recommended initial dose.ConclusionDue to lower incidence of severe ADRs with OXC than CBZ, we suggest OXC as a first-line prescription.© Copyright: Yonsei University College of Medicine 2020.

28 keywords...

hide…